• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vet Microbiol . Development of a replication-restricted, esterase-deficient influenza D virus as a live vaccine candidate

tetano

Editor, Senior Moderator
Vet Microbiol


. 2026 Jun 26:320:111129.
doi: 10.1016/j.vetmic.2026.111129. Online ahead of print.
Development of a replication-restricted, esterase-deficient influenza D virus as a live vaccine candidate

Yiyu Xu[SUP] 1 [/SUP], Misa Katayama[SUP] 1 [/SUP], Kaixin Li[SUP] 1 [/SUP], Akiko Takenaka-Uema[SUP] 1 [/SUP], Wataru Sekine[SUP] 1 [/SUP], Taisuke Horimoto[SUP] 2 [/SUP], Shin Murakami[SUP] 3 [/SUP]


Affiliations
Abstract

Influenza D virus (IDV) is an emerging bovine respiratory pathogen associated with bovine respiratory disease complex (BRDC), highlighting the need for a safe and effective live attenuated vaccine. In this study, we developed a replication-restricted IDV vaccine candidate by introducing a point mutation (S57Q) into the esterase active site of the hemagglutinin-esterase-fusion (HEF) protein, rendering the virus incapable of replication in conventional host cells. To enable efficient virus production, we established a swine testis (ST) cell line expressing wild-type HEF under a doxycycline-inducible Tet-On system, allowing controlled complementation of viral replication in trans. The rescued rD/OK-HEF-S57Q virus replicated exclusively in HEF-induced ST-Tet-On-HEF cells and exhibited no detectable replication in the respiratory tract of mice following intranasal inoculation, indicating a highly attenuated phenotype in vivo. Despite this strict replication restriction, intranasal immunization elicited robust virus-specific systemic IgG and mucosal IgA responses and conferred complete protection against challenge with wild-type IDV, with viral titers reduced below the limit of detection in both nasal turbinates and lungs. These findings highlight the potential of rD/OK-HEF-S57Q as a safe and effective live attenuated vaccine candidate for IDV.

Keywords: Bovine respiratory disease complex; Esterase; Influenza D virus; Vaccine.

 
Back
Top